Oura Health filed confidential IPO paperwork in late December, disclosing for the first time that 16% of its $295M trailing twelve-month revenue derives from licensing aggregated health data to third parties. The company sells its $299-$549 ring hardware to 2.3M users globally, but the S-1 filing shows a business model expanding beyond consumer sales into institutional data contracts.
The Finnish company signed 11 new licensing agreements in 2024, primarily with pharmaceutical companies conducting sleep disorder research and longevity-focused biotech firms. Oura's platform collects continuous heart rate variability, body temperature fluctuations, respiratory rate, and sleep architecture data from users who opt into research programs. The company reports 68% of active ring users consent to anonymized data sharing, creating a dataset covering 1.56M individuals across 42 countries. Licensing contracts typically run 24-36 months with minimum guarantees in the $2.8-$4.2M range per institutional partner.
The disclosure arrives as wearable health companies face margin pressure on hardware sales. Whoop, Oura's chief competitor, remains private but industry observers estimate its subscription-only model generates $400M annually at 40% gross margins. Oura's blended gross margin sits at 61%, with data licensing carrying estimated margins above 80% since infrastructure costs are largely fixed. The company spent $34M on cloud computing and data security in 2024, supporting both consumer app functionality and institutional data pipelines. Three pharmaceutical partners now account for $18M of licensing revenue, introducing concentration risk that the filing acknowledges but does not fully quantify.
The data commercialization strategy separates Oura from Apple and Samsung, whose privacy architectures prevent similar licensing. Apple processes health data on-device and encrypts cloud backups end-to-end, making aggregated studies difficult. Oura's Terms of Service, updated in March 2024, explicitly grant the company rights to "de-identified health insights for research and commercial purposes." Privacy advocates flagged the language, but consumer churn remained under 7% monthly, suggesting limited user resistance. The company hired a Chief Privacy Officer from 23andMe in August and added two outside directors with healthcare compliance backgrounds ahead of the filing.
Allocators should track three developments through Q2 2025. First, whether Oura prices its IPO at a revenue multiple above 8x, which would value data licensing at a premium to hardware sales and signal investor appetite for biometric data businesses. Second, any partnership announcements with GLP-1 manufacturers, who need longitudinal metabolic data as drugs move beyond diabetes into broader use. Third, regulatory commentary from the FDA or European data protection authorities on wearable data commercialization, which could force structural changes to consent frameworks.
Oura's largest institutional customer, a European pharmaceutical company unnamed in the filing, contributed $8.2M in 2024 and has an option to expand its dataset access for an additional $12M over two years. The contract renews in September 2025.